Last reviewed · How we verify
GB261
At a glance
| Generic name | GB261 |
|---|---|
| Sponsor | Genor Biopharma Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of GB261 in Systemic Sclerosis (EARLY_PHASE1)
- An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus (PHASE1)
- A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GB261 CI brief — competitive landscape report
- GB261 updates RSS · CI watch RSS
- Genor Biopharma Co., Ltd. portfolio CI